Additional file 1: Table S1. of The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry

Patient characteristics for the overall group with those receiving an ACE inhibitor other than ramipril being excluded (nâ =â 151) and split by RCT eligibility at baseline and availability of the 12-month follow-up. (DOC 53 kb)